Serum S100A12: A Risk Marker or Risk Factor of Vascular Calcification in Chronic Kidney Disease?

American Journal of Nephrology

Volumn 42, Issue , 2015, Pages 1-3

  Lindholm, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; AMYLOID; C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; CALGRANULIN; CELL ADHESION MOLECULE; FETUIN A; FIBROBLAST GROWTH FACTOR 23; HIGH MOBILITY GROUP B PROTEIN; INTERLEUKIN 6; MESSENGER RNA; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; PROTEIN S 100; S100 CALCIUM BINDING PROTEIN A12; UNCLASSIFIED DRUG; CALGRANULIN C; S100A12 PROTEIN, HUMAN;

ALBUMIN BLOOD LEVEL; ARTERIAL WALL THICKNESS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CORONARY ARTERY CALCIFICATION; ENDOTHELIUM CELL; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INTRACELLULAR SIGNALING; LIGAND BINDING; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; VASCULITIS; EDITORIAL; RISK FACTOR; BLOOD; CALCINOSIS; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DISEASE COURSE; FEMALE; MALE;

CALCINOSIS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; RENAL INSUFFICIENCY, CHRONIC; S100A12 PROTEIN;

EID: 84941996915     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000438873     Document Type: Review

References (17)

1. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle Clin J Am Soc Nephrol 2008; 3: 505-521.
2. Liabeuf S, Okazaki H, Desjardins L, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A, Martinez-Castelao A, Lindholm B, Suleymanlar G, Mallamaci F, Zoccali C, London G, Massy ZA: Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario Nephrol Dial Transplant 2014; 29: 1275-1284.
3. Wang Y, Sun Y, Wang Y, Jia Y: Serum S100A12 and progression of coronary artery calcification over 4 years in hemodialysis patients. Am J Nephrol 2015; 42: 4-13.
4. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
5. Leurs P, Lindholm B: The AGE-RAGE pathway and its relation to cardiovascular disease in patients with chronic kidney disease. Arch Med Res 2013; 44: 601-610.
6. Cohen MM Jr: Perspectives on RAGE signaling and its role in cardiovascular disease. Am J Med Genet A 2013; 161A:2750-2755.
7. Mori Y, Kosaki A, Kishimoto N, et al: Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol 2009; 29: 18-24.
8. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Bárány P, Heimbürger O, Stenvinkel P, Lindholm B: Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 2213-2219.
9. Isoyama N, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimburger O, Bárány P, Stenvinkel P, Lindholm B: Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. Nephrol Dial Transplant 2015; 30: 84-91.
10. Hara M, Ando M, Morito T, Nokiba H, Iwasa Y, Tsuchiya K, Nitta K: S100A12 gene expression is increased in peripheral leukocytes in chronic kidney disease stage 4-5 patients with cardiovascular disease. Nephron Clin Pract 2013; 123: 202-208.
11. Yan L, Mathew L, Chellan B, Gardner B, Earley J, Puri TS, Hofmann Bowman MA: S100/calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end productsdependent manner. Arterioscler Thromb Vasc Biol 2014; 34: 1399-1411.
12. Gawdzik J, Mathew L, Kim G, Puri TS, Hofmann Bowman MA: Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease. Am J Nephrol 2011; 33: 250-259.
13. Yan L, Bowman MA: Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23. Inflamm Cell Signal 2014; 1:pii:e279.
14. Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, Kang SW, Choi KH, Kim HJ, Yoo TH: Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (ENRAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis 2012; 220: 208-214.
15. Shiotsu Y, Mori Y, Hatta T, Maki N, Iida K, Matsuoka E, Kado H, Ishida R, Kishimoto N, Tamagaki K, Nishimura M, Iwamoto N, Ono T, Matsubara H, Kosaki A: Plasma S100A12 levels and peripheral arterial disease in endstage renal disease. Nephron Extra 2011; 1: 242-250.
16. Kim HS, Chung W, Kim AJ, Ro H, Chang JH, Lee HH, Jung JY: Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels. Nephrology (Carlton) 2013; 18: 777-782.
17. Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T, Maki N, Iida K, Iwamoto N, Ono T, Matsuoka E, Kishimoto N, Tamagaki K, Matsubara H, Kosaki A: Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 718-723.